Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
135
-
Total 13F shares, excl. options
-
49.9M
-
Shares change
-
+1.18M
-
Total reported value, excl. options
-
$1.22B
-
Value change
-
+$35.6M
-
Put/Call ratio
-
0.2
-
Number of buys
-
87
-
Number of sells
-
-40
-
Price
-
$24.42
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2020
153 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 135 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.9M shares
of 105M outstanding shares and own 47.65% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.44M shares), JPMORGAN CHASE & CO (4.03M shares), WELLINGTON MANAGEMENT GROUP LLP (3.76M shares), ArrowMark Colorado Holdings LLC (3.58M shares), FRANKLIN RESOURCES INC (3.47M shares), Essex Woodlands Management, Inc. (3.34M shares), VANGUARD GROUP INC (2.89M shares), ALLIANCEBERNSTEIN L.P. (2.79M shares), Capital World Investors (2.13M shares), and JENNISON ASSOCIATES LLC (2.13M shares).
This table shows the top 135 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.